Clinical study of Qinghuatan Dampness prescription for treating patients with Non-lactating mastitis (phlegm-dampness syndrome)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400084115

Enrollment

Unknown

Registered

2024-05-10

Start date

2024-05-10

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-lactating mastitis

Interventions

traditional Chinese medicine group:Prescription: Qinghuatanshi Formula. Drug composition: Pinellia ternata 9g, Coptis chinensis 6g, Scutellaria baicalensis 9g, Gardenia jasminoides 6g, Chenpi 6g, Pori

western medicine group:Bromocriptine mesylate (trade name: Baimoting, manufacturer: Hungary Geri Pharmaceutical Factory, batch number: T09478A, specification: 2.5mg/tablet).

combination group:Qinghuatanshi Formula+Bromocriptine mesylate

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Patients who meet the clinical diagnostic criteria for acne mastitis and the traditional Chinese medicine syndrome differentiation criteria for phlegm dampness syndrome; (2) Patients with visible secretion inside the catheter during surgery; (3) Age between 18 and 60 years old; (4) Lesion range = 2 quadrants (5) Non pregnant and non lactating women; (6) Be informed of the research content and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with severe primary diseases such as heart, cerebrovascular, liver, kidney, and hematopoietic system; (2) Concomitant history of pituitary microadenomas, psychiatric disorders, and malignant tumors; (3) Take drugs related to lipid metabolism and suffer from diabetes, metabolic syndrome, thyroid disease and other related abnormal lipid metabolism diseases within 2 weeks; (4) There are other primary diseases that require long-term medication to affect the research results; (5) Intolerant to the treatment process;

Design outcomes

Primary

Measure	Time frame
Clinical cure rate;	—

Secondary

Measure	Time frame
Clinical manifestations score of postoperative stress symptoms;Volume of drainage;Wound healing level;Recurrence rate;new occurrence rate;	—

Countries

China

Contacts

Public ContactHua Wan

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

drwanhua@126.com+86 21 5382 7363

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026